Vaxil Bio (VXL) AI Stock Analysis

• Market Cap: C$520.52K
• Dividend Yield: N/A
• Average Volume (3M): 1.93K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.65
• Revenue Growth: N/A
• EPS Growth: 8.35%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 2,739,579
• 10 Day Avg. Volume: 1,203
• 30 Day Avg. Volume: 1,930
• PEG Ratio: >-0.01
• Price to Book (P/B): 39.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -117.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Vaxil Bio's overall score is primarily driven by its significant financial challenges, including a lack of revenue, persistent losses, and cash flow difficulties. The stable balance sheet with no debt is a positive aspect but is overshadowed by operational inefficiencies. Technical analysis indicators are absent, providing no clarity on stock trends, while valuation concerns arise from negative earnings. The absence of earnings call data and corporate events further reduces the score's potential uplift.

Vaxil Bio Business Overview & Revenue Model

Company Description

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.

How the Company Makes Money

Vaxil Bio generates revenue primarily through the development and commercialization of its immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and potential milestone payments associated with the advancement of its pipeline candidates. Additionally, Vaxil may seek to monetize its proprietary technology platform through collaborations with larger pharmaceutical companies, which can lead to upfront payments and royalties on sales of successfully commercialized products. However, as a biotechnology firm, Vaxil's revenue may be limited until its products reach later stages of development or receive regulatory approval, at which point sales and distribution could significantly contribute to its earnings.

Vaxil Bio Financial Statement Overview

Summary

Vaxil Bio faces significant challenges with no revenue generation and consistent financial losses impacting income statements. While the balance sheet remains stable with no debt, cash flow issues highlight operational sustainability concerns. The company must focus on revenue growth and operational efficiency to improve its financial health.

Income Statement

Vaxil Bio shows no revenue generation in the past periods, resulting in negative gross and net profit margins. The EBIT and EBITDA margins are also negative due to the absence of revenue, reflecting operational inefficiencies or high fixed costs. A lack of revenue growth highlights challenges in scaling operations or product commercialization.

Balance Sheet

The company's balance sheet shows stability with no debt and a positive equity position, indicating financial resilience and low leverage risk. However, the equity ratio has decreased over recent periods, suggesting a relative increase in liabilities. Nevertheless, the absence of debt reduces bankruptcy risk.

Cash Flow

Vaxil Bio's cash flow from operations is consistently negative, indicating challenges in sustaining operations without external financing. However, free cash flow has shown some improvement over the TTM, although it remains negative, suggesting continued operational cash burn without revenue offsets.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-2.00K	-25.00K	-57.00K
EBITDA	-189.00K	-178.00K	-252.00K	-582.00K	-961.00K	-1.29M
Net Income	-99.00K	-178.00K	-254.00	-584.00K	-986.00K	-1.36M
Balance Sheet
Total Assets	697.00K	733.00K	976.00K	1.54M	2.29M	1.66M
Cash, Cash Equivalents and Short-Term Investments	347.00K	714.00K	938.00K	1.51M	2.24M	1.51M
Total Debt	0.00	0.00	0.00	0.00	0.00	9.00K
Total Liabilities	6.00K	17.00K	85.00K	405.00K	585.00K	857.00K
Stockholders Equity	691.00K	716.00K	891.00K	1.14M	1.70M	804.00K
Cash Flow
Free Cash Flow	-157.08K	-240.00K	-561.00K	-734.00K	-1.08M	-1.10M
Operating Cash Flow	-157.08K	-240.00K	-561.00K	-734.00K	-1.08M	-1.10M
Investing Cash Flow	0.00	-250.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	0.00	0.00	0.00	0.00	1.81M	2.56M

Vaxil Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VXL	35 Underperform	C$520.52K	―	-14.21%	―	―	8.35%
NSHS	30 Underperform	C$308.26K	0.88	8.55%	―	―	―

Vaxil Bio Corporate Events

Vaxil Bio and Green Data Centers Terminate Agreement

Vaxil Bio Ltd. announced the mutual termination of its definitive agreement with Green Data Center Real Estate Inc. This move will see Green Data Centers repay a loan from Vaxil by July 2025 and issue shares worth $50,000 to Vaxil. Despite this, Vaxil remains committed to exploring other strategic options to maximize shareholder value, including the further development of its existing assets.